169 related articles for article (PubMed ID: 30275685)
1. Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer.
Li S; Wei W; Jiang Y; Li Q; Huang Q; Yang H; Liu J
Drug Des Devel Ther; 2018; 12():3085-3093. PubMed ID: 30275685
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer.
Zhang M; Wei W; Liu J; Yang H; Jiang Y; Tang W; Li Q; Liao X
Onco Targets Ther; 2016; 9():3443-50. PubMed ID: 27354816
[TBL] [Abstract][Full Text] [Related]
3. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Ueno T; Masuda N; Sato N; Ohtani S; Yamamura J; Matsunami N; Kashiwaba M; Takano T; Takahashi M; Kaneko K; Ohno S; Morita S; Toi M
Jpn J Clin Oncol; 2020 Jan; 50(1):3-11. PubMed ID: 31821506
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
Jinno H; Sakata M; Hayashida T; Takahashi M; Mukai M; Ikeda T; Kitagawa Y
Ann Oncol; 2010 Jun; 21(6):1262-1266. PubMed ID: 19854722
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Earl HM; Hiller L; Dunn JA; Blenkinsop C; Grybowicz L; Vallier AL; Abraham J; Thomas J; Provenzano E; Hughes-Davies L; Gounaris I; McAdam K; Chan S; Ahmad R; Hickish T; Houston S; Rea D; Bartlett J; Caldas C; Cameron DA; Hayward L;
Lancet Oncol; 2015 Jun; 16(6):656-66. PubMed ID: 25975632
[TBL] [Abstract][Full Text] [Related]
7. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Ishiguro H; Masuda N; Sato N; Higaki K; Morimoto T; Yanagita Y; Mizutani M; Ohtani S; Kaneko K; Fujisawa T; Takahashi M; Kadoya T; Matsunami N; Yamamoto Y; Ohno S; Takano T; Morita S; Tanaka-Mizuno S; Toi M
Breast Cancer Res Treat; 2020 Apr; 180(3):715-724. PubMed ID: 32170634
[TBL] [Abstract][Full Text] [Related]
8. Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Vinnyk Y; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Moiseyenko V; Shparyk Y; Bello M; Semiglazov V; Song S; Lim J
J Clin Oncol; 2018 Apr; 36(10):968-974. PubMed ID: 29373094
[TBL] [Abstract][Full Text] [Related]
9. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
10. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
Foldi J; Mougalian S; Silber A; Lannin D; Killelea B; Chagpar A; Horowitz N; Frederick C; Rispoli L; Burrello T; Abu-Khalaf M; Sabbath K; Sanft T; Brandt DS; Hofstatter EW; Hatzis C; DiGiovanna MP; Pusztai L
Breast Cancer Res Treat; 2018 Jun; 169(2):333-340. PubMed ID: 29396664
[TBL] [Abstract][Full Text] [Related]
11. Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer.
Veitch Z; Khan OF; Tilley D; Ribnikar D; Kostaras X; King K; Tang P; Lupichuk S
J Natl Compr Canc Netw; 2019 Jan; 17(1):47-56. PubMed ID: 30659129
[No Abstract] [Full Text] [Related]
12. [Analysis of neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) in HER-2-positive breast cancer].
Xu L; Ye JM; Zhu SN; Zhao JY; Xin L; Cheng YJ; Liu Q; Zhang H; Zhang S; Duan XN; Liu YH
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(12):907-911. PubMed ID: 29665663
[No Abstract] [Full Text] [Related]
13. [Docetaxel, carboplatin plus trastuzumab as neoadjuvant setting in patients with early-stage human epidermal growth factor receptor 2 positive breast cancer: a retrospective analysis].
Xin L; Zhang H; Zhang S; Cheng YJ; Liu Q; Xu L; Ye JM; Li T; Duan XN; Liu YH; Li ZH
Zhonghua Wai Ke Za Zhi; 2021 Mar; 59(3):222-227. PubMed ID: 33685057
[No Abstract] [Full Text] [Related]
14. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Chow LW; Tung SY; Ng TY; Im SA; Lee MH; Yip AY; Toi M; Glück S
Expert Opin Investig Drugs; 2013 Mar; 22(3):299-307. PubMed ID: 23394482
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
Tiwari SR; Mishra P; Raska P; Calhoun B; Abraham J; Moore H; Budd GT; Fanning A; Valente S; Stewart R; Grobmyer SR; Montero AJ
Breast Cancer Res Treat; 2016 Jul; 158(1):189-193. PubMed ID: 27324504
[TBL] [Abstract][Full Text] [Related]
16. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
[TBL] [Abstract][Full Text] [Related]
17. Cardiac safety of neoadjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel/pertuzumab/trastuzumab for HER2-positive breast cancer patients.
Douganiotis G; Grigoriadis S; Kontovinis L; Markopoulou E; Pouptsis A; Papazisis K
J BUON; 2021; 26(3):714-719. PubMed ID: 34268925
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.
Heller W; Mazhar D; Ward R; Sinnett HD; Lowdell C; Phillips R; Shousha S; Fayaz A; Palmieri C; Coombes RC
Oncol Rep; 2007 Jan; 17(1):253-9. PubMed ID: 17143506
[TBL] [Abstract][Full Text] [Related]
19. Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.
Holmes FA; Hellerstedt BA; Pippen JE; Vukelja SJ; Collea RP; Kocs DM; Blum JL; McIntyre KJ; Barve MA; Brooks BD; Osborne CR; Wang Y; Asmar L; O'Shaughnessy J
Cancer Med; 2018 Jun; 7(6):2288-2298. PubMed ID: 29582557
[TBL] [Abstract][Full Text] [Related]
20. Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
Fujita N; Fujita K; Kim SJ; Iguchi C; Nomura T; Aono T; Yanagisawa T; Enomoto Y; Inakami K; Miyagawa Y; Tomoike R; Kasugai T; Shiba E
Oncology; 2022; 100(5):257-266. PubMed ID: 35114682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
